Michael Davidson, NewAmsterdam CEO
July 25, 2022 10:04 AM EDTUpdated 10:28 AM
Financing
Deals

NewAms­ter­dam's bid to re­vive Am­gen car­dio drug heads to Nas­daq in Fra­zier SPAC deal

Kyle LaHucik

Senior Reporter

Five years af­ter Am­gen buried its CETP cho­les­terol drug, a Dutch biotech with hun­dreds of mil­lions in fund­ing is head­ed to Wall Street to con­tin­ue …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times